MAPT and Alzheimer disease: Using a sample size of 98 participants across the AD spectrum, Schwarz and colleagues [10] found that all three schemes displayed a high concordance between tau positivity and Aβ positivity (82%–96%), with only 35% to 41% of Aβ positive participants being classified as tau negative.